Promising
Gonadorelin (GnRH)
The prediction game
Call it: rising or fading?
Where does Gonadorelin (GnRH) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: B (good evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 6.3/10
Gonadorelin lands at Neutral because it pairs a genuinely strong foundation with a borrowed headline and finicky execution. It is a real, formerly FDA-approved drug with a textbook-clear, reversible mechanism, and it is the master hormone of the reproductive axis. Those qualities lift it above many peptides. What caps it is that the use driving current demand, keeping the testes working on testosterone therapy, is extrapolated from hCG data rather than proven directly, per Hsieh 2013, the dosing is fragile because the half-life is minutes and the pattern must be pulsed, and most supply is compounded or grey-market. Get the dosing right and source it well and you sit at the upper end; navigate an awkward microdose schedule and uncertain supply and you sit at the headline score. ✅ Best for: TRT users with an intact pituitary who want to keep their testes working and preserve fertility, and who will commit to frequent, well-timed pulsed dosing; people who understand that hCG is the better-tested tool for the same fertility goal and are choosing gonadorelin deliberately, often during an hCG shortage; clinicians managing genuine hypothalamic amenorrhea who can deliver true pulses by pump for physiological, low-hyperstimulation ovulation, per Martin and Crowley 1990; clinicians inducing fertility in male hypogonadotropic hypogonadism who accept the logistical demands of pulsatile delivery, per Dwyer 2024. ❌ Avoid if: you want a set-and-forget injection, because the pulse pattern is the entire point and overly frequent dosing can suppress the axis, per Belchetz 1978; your pituitary itself is the problem, since gonadorelin needs a responsive pituitary downstream to work, per Zheng 2017; you cannot verify your source, because compounded and grey-market supply dominates and carries identity, sterility, and dose uncertainty; or you would be better served by the directly-tested hCG adjunct for the same goal, per Coviello 2005. For related melanocortin peptides outside this axis, see the PT-141 and Melanotan I reports.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Promising
- Trend
- Begins with Edition 2
- Momentum
- 2.2%
- BioHarmony Score
- 6.3/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.